Home » Newsletters » BioWorld Science

BioWorld Science

June 28, 2001

View Archived Issues

Licensing opportunity from NIH: methods of treating cancer, diabetes based on adrenomedullin

Available for licensing from the NIH: novel inhibitors of p53

InKine's Colirest enters pivotal trial for IBD

Glycogen phosphorylase inhibitor + metformin combinations effective and safe in ob/ob mice

Genistein derivative shows raloxifene-like SERM profile

Antidiabetic effects and excellent pharmacokinetics described for new PTP1B inhibitor

Novartis prepares new somatostatin analogues with improved therapeutic profile

Bone remodeling reduced by TSE-424 in prospective trial in postmenopausal women

Ciprofloxacin GR proves suitable for once-daily dosing in phase I study

GenVec and Varian Medical extend collaborative agreement for treatment of cancer

GPC Biotech delivers seven antimicrobial targets to Byk Gulden

Long-term therapy with DPP IV inhibitor may be beneficial in diabetes

Japanese regulatory agency approves Allergan's Botox for cervical dystonia

NCX-701 shows good bioavailability and safety in phase I

AstraZeneca seeks U.S. and European approval of new superstatin Crestor

FDA advisory committee to discuss NDA for Remodulin in August

Development of Viozan discontinued

SuperGen's DHEA phosphocholine demonstrates antidiabetic potential

AstraZeneca files sNDA seeking new indications for Merrem I.V.

Oral insulin formulations devised by Emisphere effective in animals, progress to the clinic

Neutralase used for first time in congenital heart procedure

Potent and selective factor Xa inhibitors useful as anticoagulants

Fujisawa's Protopic approved in Canada

A-76202 analogues inhibit alpha-glucosidase, useful for diabetes, obesity, AIDS

Boehringer Ingelheim claims new CRGP antagonists and uses thereof

Several related series of compounds identified at Merck as NMDA antagonists

Cytokinetics and GlaxoSmithKline establish cancer drug discovery alliance

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...